Post-approval studies (Phase 4)Study completedNCT01495221
What this trial is testing
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
Who this might be right for
AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
Vitreous -Retina- Macula Consultants of New York 9